Home LiteratureArticle Details
PMID: 1906791 Published · ppublish English Clinical Trial Controlled Clinical Trial Journal Article Research Support, Non-U.S. Gov't

The lack of interaction between temafloxacin and combined oral contraceptive steroids.

Contraception ·Vol. 43 ·No. 4 ·1991-04-00 ·Pages 317-23

Back DJ, Tjia J, Martin C, Millar E, Mant T, Morrison P, Orme M

Abstract

In view of the considerable debate concerning the possible failure of contraception in women taking broad spectrum antibiotics, we have examined a group of 12 women aged 22-32 in a controlled study. Each woman had been on long-term therapy with oral contraceptive steroids (OCS) containing ethynylestradiol (EE2) and levonorgestrel (Ng) for at least 6 months and all were in good general health. Blood samples were taken about 11.0 hours after dosing with their OCS on days 5, 6, 7 and 8 of their contraceptive cycle, for measurement of EE2, Ng, FSH and LH by radioimmunoassay. In addition blood samples were taken on days 19, 20 and 21 of the contraceptive cycle for assay of progesterone concentrations in plasma. The study was repeated in the next cycle of use of their OCS during which they took temafloxacin, a broad spectrum quinolone antibiotic in a dose of 600 mg twice daily for 7 days starting on day 1 of the cycle. All women completed the study satisfactorily as judged by diary cards, tablet counts and plasma temafloxacin concentrations. In the early part of the study some nausea and headaches were seen due to taking temafloxacin on an empty stomach but these effects were not seen when the antibiotic was later given with food. There was no evidence of any interaction between temafloxacin and the OCS. The plasma concentration of EE2 was 61.4 +/- 21.1 pg/ml in the control cycle and 68.5 +/- 26.6 pg/ml in the temafloxacin cycle.(ABSTRACT TRUNCATED AT 250 WORDS)

Keywords
Antibiotics Biology Contraception Contraceptive Agents Estrogen--analysis Contraceptive Agents Female--analysis Contraceptive Agents--analysis Contraceptive Methods Developed Countries Drug Interactions Drugs Endocrine System Ethinyl Estradiol--analysis Europe Examinations And Diagnoses Family Planning Follicle Stimulating Hormone--analysis Gonadotropins Gonadotropins Pituitary Hormones Laboratory Examinations And Diagnoses Luteinizing Hormone--analysis Northern Europe Oral Contraceptives Oral Contraceptives Combined Physiology Treatment United Kingdom
MeSH Terms
4-Quinolones Adult Anti-Infective Agents/pharmacology Contraceptives, Oral, Combined/pharmacokinetics Drug Interactions Ethinyl Estradiol/pharmacokinetics Female Fluoroquinolones Follicle Stimulating Hormone/blood Humans Levonorgestrel Luteinizing Hormone/blood Norgestrel/pharmacokinetics Progesterone/blood Quinolones Radioimmunoassay
Chemicals
4-Quinolones Anti-Infective Agents Contraceptives, Oral, Combined Fluoroquinolones Quinolones temafloxacin Norgestrel Ethinyl Estradiol Progesterone Levonorgestrel Luteinizing Hormone Follicle Stimulating Hormone
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Back D J
Department of Pharmacology and Therapeutics, Liverpool University, England.
Tjia J
Martin C
Millar E
Mant T
Morrison P
Orme M
Other Abstracts
eng

In view of the considerable debate concerning the possible failure of contraception in women taking broad spectrum antibiotics, the authors examined a group of 12 women ages 22-32 in a controlled study. Each had been on longterm therapy with oral contraceptives (OCs) containing ethinyl estradiol (EE) and levonorgestrel (Ng) for at least 6 months and all were in good general health. Blood samples were taken about 11.0 hours after dosing with OCs on days 5, 6, 7, and 8 of their contraceptive cycle, for measurement of EE2, Ng, FSH, and LH by radioimmunoassay. In addition, blood samples were taken on days 19, 20, and 21 of their contraceptive cycle for assay of progesterone concentrations in plasma. The study was repeated in the next cycle of OC use during which the patients took temafloxacin, a broad spectrum quinoline antibiotic in a dose of 600 mg twice daily for 7 days, beginning on day 1 of the cycle. All women completed the study satisfactorily as judged by diary cards, tablet counts, and plasma temafloxacin concentrations. In the early part of the study, some nausea and headaches were experienced

this was due to the taking of the drug on an empty stomach. When the antibiotic was administered with food, this problem was no longer a concern. There was no evidence of any interaction between temafloxacin and OCs. The plasma concentration of EE2 was 61.4 +or- 21.2 pg/ml in the control cycle and 68.5 +or- 26.6 pg/ml in the temafloxacin cycle. The plasma progesterone concentration was 0.53 +or- 0.1 ng/ml in the control cycle and 0.6 +or- 0.24 ng/ml in the temafloxacin cycle (p0.01). No woman demonstrated any significant rise in plasma FSH or LH concentrations during temafloxacin therapy. The authors conclude that there is no evidence for a systematic interaction between temafloxacin and OCs and that there is no need for use of alternative contraceptive methods in women taking OCs who are also being treated with temafloxacin.

Article Info
Journal
Contraception
Abbr.
Contraception
ISSN
0010-7824
Published
1991-04-00
Pages
317-23
Language
English
Region
United States
NLM ID
0234361
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com